No adverse events (e.g., hypoglycemia, ketoacidosis) occurred, and the regimen was well-tolerated.<h4>Conclusion</h4>This study provides preliminary clinical evidence for KD in PTEN-related ASD, suggesting potential modulation of the PI3K/AKT/mTOR pathway and neuroinflammation. The gene discussed is AKT1; the disease is Hypoglycemia.